Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MiMedx Group Inc (MDXG), Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): A Trio of Horrendous Health-Care Stocks This Week

College football arrived in a big way over the past week or so, with plenty of big plays already. Health-care stocks had their fair share of big plays, also — with some not going so well. Here are three of the worst health-care stocks over the last week.

Untitled letter blues

An “untitled letter” posted by the U.S. Food and Drug Administration on its website sent shares of MiMedx Group Inc (NASDAQ:MDXG) on a wild ride this week. After plunging by as much as 70%, the stock rebounded to end the week down nearly 32%.

MiMedx Group Inc (NASDAQ:MDXG)

The FDA alleged that MiMedx Group Inc (NASDAQ:MDXG) marketed its micronized injectable wound care products without first obtaining approval as a biologic. MiMedx strongly disagreed with the FDA’s opinion and quickly moved to schedule a conference call to discuss the situation. CEO Bill Taylor expressed surprise with the FDA letter, stating that the agency conducted an inspection more than a year ago, and that no issues were identified following the inspection.

While the market reaction to the news was swift and severe, MiMedx Group Inc (NASDAQ:MDXG) reiterated its revenue projections for 2013 and 2014. The company said it is working with the FDA to resolve any issues.

Breath-taking news

Biopharmaceuticals company Cytokinetics, Inc. (NASDAQ:CYTK) saw its stock get clobbered by an all-too-common malady in the world of biotech: disappointing clinical study results. Shares fell more than 18% for the week.

On Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and partner Amgen, Inc. (NASDAQ:AMGN) announced results from a phase 2 study of omecamtiv mecarbil in treating acute heart failure. The companies said that the primary endpoint of the study, improved dyspnea, or shortness of breath, response, had not been met.

Omecamtiv mecarbil is also being evaluated in another phase 2 study in treating chronic heart failure. Amgen, Inc. (NASDAQ:AMGN)’s executive vice president of research and development, Sean E. Harper, M.D, said the results from both studies would be used to determine whether the drug would advance to late-stage clinical trials.

Off-key musical chairs?

Maybe the third time will prove to be the charm for VIVUS, Inc. (NASDAQ:VVUS). The weight-loss-drug company announced its third CEO in less than two months this week. Shares fell more than 12% for the week.

Anthony Zook resigned as CEO of VIVUS effective Tuesday. Zook’s departure stemmed from “recurring issues associated with a previously diagnosed medical condition”, according to the company. VIVUS already had his replacement lined up. Former Johnson & Johnson executive Seth Fischer has now assumed the helm as CEO.

Initially, the market didn’t initially seem very concerned about the musical chairs at the top of VIVUS, Inc. (NASDAQ:VVUS), as shares closed up a little on the day the CEO change was announced. However, the stock began falling on Wednesday and continued to drop on Thursday.

Bouncing back

All three of this week’s big losers face real challenges. As always, investors should exercise caution in jumping into these stocks.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.